Smoldering Multiple Myeloma (SMM)
What Is Smoldering Multiple Myeloma?
Smoldering Multiple Myeloma (SMM), also called asymptomatic myeloma, is an intermediate condition between MGUS (benign) and active multiple myeloma (cancer).
Key characteristics of SMM:
- Higher levels of abnormal protein than MGUS
- More plasma cells in the bone marrow (10-60%)
- No symptoms or organ damage
- No treatment needed yet; active monitoring instead
- May remain stable for years or progress to active myeloma
Important: SMM is not yet cancer requiring treatment. It is a pre-cancerous condition that requires careful monitoring.
How SMM Is Diagnosed
SMM is diagnosed when the following criteria are met:
- M protein level: >= 3 g/dL in blood, or >= 500 mg/24 hours in urine
- Bone marrow plasma cells: 10-60%
- No symptoms or complications: No bone lesions, anemia, kidney dysfunction, or high calcium (no CRAB features)
If symptoms or organ damage develop, the diagnosis changes to active multiple myeloma.
SMM vs. MGUS vs. Multiple Myeloma
| Feature | MGUS | SMM | Active Myeloma |
|---|---|---|---|
| M protein | < 3 g/dL | >= 3 g/dL | Variable (often high) |
| Plasma cells (bone marrow) | < 10% | 10-60% | >= 10% (often higher) |
| Symptoms | None | None | Present (bone pain, fatigue, etc.) |
| Organ damage | None | None | Present (CRAB criteria) |
| Treatment | Monitoring only | Monitoring (or clinical trial) | Active treatment required |
| Progression risk | ~1% per year | ~10% per year (first 5 years) | N/A |
Risk of Progression to Active Myeloma
SMM progresses to active multiple myeloma at a rate of approximately 10% per year for the first 5 years, then decreases over time.
Overall risk:
- After 5 years: ~50% progress
- After 10 years: ~65-75% progress
- Some individuals remain stable for many years
Risk Stratification
Risk varies based on several factors:
Low-risk SMM:
- Lower M protein levels
- Lower plasma cell percentage
- Normal free light chain ratio
- Progression risk closer to MGUS (~5% per year)
High-risk SMM:
- M protein > 2 g/dL
- Bone marrow plasma cells > 20%
- Abnormal free light chain ratio (<0.125 or >8)
- Progression risk ~25% per year in the first 5 years
High-risk SMM may qualify for clinical trials evaluating early treatment.
Monitoring and Follow-Up
SMM requires more frequent monitoring than MGUS.
Typical monitoring schedule:
- First year: Every 2-3 months
- After 1 year (if stable): Every 3-4 months
- After 2+ years (if stable): Every 4-6 months
Tests typically monitored:
- M protein levels (blood and urine)
- Complete blood count (CBC)
- Kidney function
- Calcium levels
- Serum free light chains
- Periodic imaging (X-ray, MRI, or PET/CT)
Symptoms That Require Immediate Attention
Contact your healthcare provider immediately if you develop:
- Bone pain (especially back, ribs, or hips)
- Fractures with minimal trauma
- Severe fatigue or weakness
- Frequent infections
- Unexplained weight loss
- Confusion or excessive thirst (possible high calcium)
- Reduced urination or swelling (kidney issues)
These symptoms may indicate progression to active myeloma.
Treatment Considerations
Standard approach: Most individuals with SMM are monitored without treatment ("watchful waiting").
Why treatment is often delayed:
- Not all SMM progresses
- Treatments can have side effects
- Early treatment has not consistently improved outcomes in low-risk SMM
When treatment may be considered:
- High-risk SMM
- Ultra-high-risk features suggesting imminent progression
- Participation in clinical trials
Discuss potential options with your hematologist if you have high-risk features.
Living with SMM
Most people with SMM feel completely normal and can maintain their usual activities.
General recommendations:
- Stay active to support bone health
- Maintain a balanced diet with adequate calcium and vitamin D
- Stay up to date with vaccinations (flu, pneumonia, COVID-19)
- Stay well hydrated to support kidney function
- Keep all monitoring appointments
- Report new symptoms promptly
What About Clinical Trials?
If you have high-risk SMM, ask your doctor about clinical trials. Research is currently exploring:
- Whether early treatment can delay progression
- Which patients benefit most from intervention
- New targeted therapies with fewer side effects
Clinical trials may provide access to emerging treatments.
Related Conditions
SMM exists on a spectrum:
- MGUS: Earlier, lower-risk stage
- Multiple myeloma: Active cancer requiring treatment
- Waldenstrom macroglobulinemia: A different condition involving IgM proteins
The Bottom Line
SMM is a pre-cancerous condition that requires monitoring but usually not immediate treatment.
While the risk of progression is higher than MGUS, many people remain stable for years. The key is consistent monitoring to detect changes early.
Key takeaways:
- You may feel completely normal; SMM typically has no symptoms
- Not everyone progresses to active myeloma
- Regular monitoring is essential
- Treatment begins only if progression occurs
- High-risk patients may benefit from clinical trials
Work with your healthcare provider to develop a personalized monitoring plan based on your risk profile.
Show more